373359-51-4

Usage

Uses

Used in Pharmaceutical Industry:
Benzenamine, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)is utilized as a pharmaceutical intermediate for the development of drugs that target specific biological pathways. Its unique structure allows it to interact with biological systems in ways that could lead to the creation of novel therapeutic agents.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, Benzenamine, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)serves as a key compound for research, providing insights into the design and synthesis of new drugs with improved efficacy and selectivity.
Used in Industrial Chemical Production:
Benzenamine, 4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)may also be employed in the industrial sector for the production of specialty chemicals and materials, leveraging its distinctive properties to create innovative products with specific applications.

Upstream product

• 79421-42-4 8-(4-nitrophenyl)-1,4-dioxa-8-azaspiro[4.5]decane 
• 177-11-7 4,4-ethylenedioxy-piperidine 
• 350-46-9 4-Fluoronitrobenzene 

Downstream Products

• 373359-65-0 butyl-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenyl]amine 
• 373359-52-5 N-{4-[4-(1,4-dioxa-8-azaspiro[4.5]dec-8-yl)phenylsulfamoyl]phenyl}acetamide 
• 340757-10-0 1-[4-(butylamino)phenyl]-4-piperidinone 
• 373359-53-6 N-{4-[4-(4-oxopiperidin-1-yl)phenylsulfamoyl]phenyl}acetamide 
• 373360-07-7 {butyl[4-(4-oxopiperidin-1-yl)phenyl]sulfamoyl}acetic acid benzyl ester 

Relevant academic research and scientific papers

Identification of a Novel 2,8-Diazaspiro[4.5]decan-1-one Derivative as a Potent and Selective Dual TYK2/JAK1 Inhibitor for the Treatment of Inflammatory Bowel Disease

In this study, we described a series of 2,8-diazaspiro[4.5]decan-1-one derivatives as selective TYK2/JAK1 inhibitors. Systematic exploration of the structure-activity relationship through the introduction of spirocyclic scaffolds based on the reported selective TYK2 inhibitor 14l led to the discovery of the superior derivative compound 48. Compound 48 showed excellent potency on TYK2/JAK1 kinases with IC50 values of 6 and 37 nM, respectively, and exhibited more than 23-fold selectivity for JAK2. Compound 48 also demonstrated excellent metabolic stability and more potent anti-inflammatory efficacy than tofacitinib in acute ulcerative colitis models. Moreover, the excellent anti-inflammatory effect of compound 48 was mediated by regulating the expression of related TYK2/JAK1-regulated genes, as well as the formation of Th1, Th2, and Th17 cells. Taken together, these findings suggest that compound 48 is a selective dual TYK2/JAK inhibitor, deserving to be developed as a clinical candidate.

Novel (4-piperidin-1-yl)-phenyl sulfonamides as potent and selective human β3 agonists

A series of novel (4-piperidin-1-yl)-phenyl sulfonamides was prepared and evaluated for their biological activity on the human β3-adrenergic receptor (AR). Replacement of the 3,4-dihydroxyl group of the catechol moiety with 4-hydroxyl-3-methyl